TrialThe Lancet. Infectious diseases2018

Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study.

Alejandro Llanos-Cuentas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.